Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes

Medical Oncology

Volumn 23, Issue 1, 2006, Pages 37-49

  Tehranchi, R ^a,b  

^a Lund Strategic Research Center for Stem Cell Biology and Cell Therapy   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Apoptosis; Erythropoietin; Fas; G CSF; Mitochondria; Myelodysplastic syndrome

Indexed keywords

FERRITIN; HEMOPOIETIC GROWTH FACTOR; PROTEIN BCL 2; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; BONE MARROW; CELL DEATH; CELL DIFFERENTIATION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ERYTHROBLAST; ERYTHROID CELL; GENE MUTATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION COMPLICATION; MITOCHONDRION; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REGULATORY MECHANISM; REVIEW; RISK ASSESSMENT;

APOPTOSIS; CELL DIFFERENTIATION; DNA, MITOCHONDRIAL; ERYTHROPOIETIN; FERRITINS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 33646858141     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:1:37     Document Type: Review

References (136)

1. Hellstrom-Lindberg E, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997;99(2):344-351.
2. Hellstrom-Lindberg E, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92(1):68-75.
3. Reddy PL, et al. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes. Br J Haematol 2002;116(3): 564-575.
4. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998;83(1):71-86.
5. Aul C, Germing U, Gattermann N, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious? Leuk Res 1998;22(1):93-100.
6. Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992;82(2):358-367.
7. Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994;87(4):743-745.
8. Maynadie M, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer 1996;74(2):288-290.
9. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001;73(4):405-410.
10. Reizenstein P, Dabrowski L. Increasing prevalence of the myelodysplastic syndrome. An international Delphi study. Anticancer Res 1991;11(3):1069-1070.
11. Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 1995;54(3):153-156.
12. Germing U, et al. No evidence of increasing incidence of MDS. Leuk Res 2003;27 (suppl 1):S2.
13. Bennett JM, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51(2): 189-199.
14. Jaffe ES, et al. (eds). VJW. World health organization classification of tumours. Pathology and Genetics of tumours of haematopoietic and lymphoid tissues. IARC Press: Lyor, 2001.
15. Greenberg P, et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol 2000;18(19):3447-3452.
16. Nosslinger T, et al. Myelodysplastic syndromes, from French-American- British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001;98(10):2935-2941.
17. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24(12):983-992.
18. Bennett JM, Brunning RD, Vardiman JW. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood 2002;99(8):3074-3075.
19. Dunkley SM, Manoharan A, Kwan YL. Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts. Blood 2002;99(10): 3870-3871; author reply 3871.
20. Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood 2004;103(9):3265- 3270.
21. Garcia S, et al. Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases. Am J Hematol 1988;27(3):163-168.
22. Worsley A, et al. Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival. Br Haematol 1988;68(1):17-21.
23. Aul C, et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992;6(1):52-59.
24. Morel P, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993;7(9):1315-1323.
25. Greenberg P, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89(6):2079-2088.
26. Miller KB. Myelodysplastic syndromes. Curr Treat Options Oncol 2000;1(1):63-69.
27. Hamblin T. Clinical features of MDS. Leuk Res 1992; 16(1):89-93.
28. Koeffler HP. Myelodysplastic syndromes. Semin Hematol 1996;33(2):87-94.
29. Fadeel B, Orrenius S, Zhivotovsky B. Apoptosis in human disease: a new skin for the old ceremony? Biochem Biophys Res Commun 1999;266(3):699-717.
30. Fadeel B, Zhivotovsky B, Orrenius S. All along the watch-tower: on the regulation of apoptosis regulators. FASEB J 1999;13(13):1647-1657.
31. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407(6805):770- 776.
32. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptor-mediated apoptosis pathways. Int J Biochem Cell Biol 2000;32(11-12):1123-1136.
33. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene 2002;21(57):8786-8803.
34. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281(5381):1312-1316.
35. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997;18(1):44-51.
36. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281(5381):1309-1312.
37. Mignotte B, Vayssiere JL. Mitochondria and apoptosis. Eur J Biochem 1998;252(1):1-15.
38. Petit PX, et al. Implication of mitochondria in apoptosis. Mol Cell Biochem 1997;174(1-2):185-188.
39. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000;102(1): 33-42.
40. Zamzami N, Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol 2001;2(1):67-71.
41. Smeitink J, van den Heuvel L, DiMauro S. The genetics and pathology of oxidative phosphorylation. Nat Rev Genet 2001;2(5):342-352.
42. Loeffler M, Kroemer G. The mitochondrion in cell death control: certainties and incognita. Exp Cell Res 2000; 256(1):19-26.
43. Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S. Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci USA 2002;99(3):1259-1263.
44. Krammer PH. CD95 (APO-1/Fas)-mediated apoptosis: live and let die. Adv Immunol 1999;71:163-210.
45. Robertson JD, Fadeel B, Zhivotovsky B, Orrenius S. "Centennial" Nobel Conference on apoptosis and human disease. Cell Death Differ 2002;9(4):468-475.
46. Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int J Hematol 1993;57(2):87-97.
47. Raza A, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86(1): 268-276.
48. Parker JE, et al. "Low-risk" myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998;103(4):1075-1082.
49. Parker JE, et al. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96(12):3932-3938.
50. Boudard D, et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 2002;70(2):115-125.
51. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997;21(5):415-425.
52. Tsoplou P, et al. Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in "good" versus "poor" prognosis patients and correlation with apoptosis-related genes. Leukemia 1999;13(10):1554-1563.
53. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;88(11):4275-4287.
54. Bouscary D, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997;11(6):839-845.
55. Boudard D, et al. Expression and activity of caspases 1 and 3 in myelodysplastic syndromes. Leukemia 2000;14(12):2045-2051.
56. Dar S, et al. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol 1999;62(2):90-94.
57. Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol 2000; 110(3):584-590.
58. Ramos F, Fuertes-Nunez M, Suarez-Vilela D, Fernandez-Lopez A. What does apoptosis have to do with clinical features in myelodysplastic syndrome? Haematologica 2002;87(4):381-391.
59. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997;89(6):1845-1853.
60. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998;22(12):1123-1136.
61. Mundle SD, et al. Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 1999;60(1):36-47.
62. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol 1995;91(1):245-252.
63. Chinnaiyan AM, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271(9):4961-4965.
64. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281(5381):1305-1308.
65. De Maria R, et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999;93(3): 796-803.
66. Nagafuji K, et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995; 86(3):883-889.
67. Gersuk GM, et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103(1): 176-188.
68. Lepelley P, et al. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma 1998;30(3-4): 307-312.
69. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, Christensson B, Fadeel B, Zhivotovsky B. Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Haematol 2001;112(3):714-726.
70. Plasilova M, et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002;16(1):67-73.
71. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001;98(10):3058-3065.
72. Schmidt-Mende J, et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001;15(5):742-751.
73. Ali A, et al. Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res 1999;8(4):343-356.
74. Mundle SD, et al. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. Int J Hematol 1999;70(2):83-90.
75. Bouscary D, et al. Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol 2000;28(7):784-791.
76. Claessens YE, et al. Rescue of early stage myelodysplastic syndrome-deriving erythroid precursors by the ectopic expression of a dominant negative form of FADD. Blood 2005;105(10):4035-4042.
77. Tehranchi R, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003;101(3):1080-1086.
78. Raza A, et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996;63(4):265-278.
79. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech 2000;50(3):229-235.
80. Verhoef GE, et al. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992;6(12):1268-1272.
81. Musto P, et al. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. Haematologica 1994;79(3):265-268.
82. Silverman LR, Zinzar S, Holland JF. Biological consequences of stromal abnormalities in the myelodysplastic syndrome (MDS): Its influence on the hematopoietic dysregulation. Leuk Res 1997;21(1, Supplement 1):S20.
83. Aizawa S, et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999;23(3):239-246.
84. Tennant GB, et al. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol 2000;111(3):853-862.
85. Bogdanovic AD, et al. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997;11(5):656-659.
86. Kuhl JS, Krajewski S, Duran GE, Reed JC, Sikic BI. Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia. Br J Cancer 1997;75(2):268-274.
87. Bessho F, Ohnishi H, Tabuchi K, Kobayashi M, Hayashi Y. Significance of electron-dense deposits in the mitochondrial matrix of erythroid precursors in aplastic anaemia and myelodysplastic syndrome. Br J Haematol 1999;105(1): 149-154.
88. van de Loosdrecht AA, et al. Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis. Leuk Res 2001;25(5):385-393.
89. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341(Pt 2):233-249.
90. Matthes TW, Meyer G, Samii K, Beris P. Increased apoptosis in acquired sideroblastic anaemia. Br J Haematol 2000;111(3):843-852.
91. Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res 2000;24(2):141-151.
92. Anderson S, et al. Sequence and organization of the human mitochondrial genome. Nature 1981;290(5806):457-465.
93. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988;85(17):6465-6467.
94. Gattermann N, Aul C. Mitochondrial DNA amplification in AML: a hypothesis. Br J Haematol 1997;97(1):242.
95. Taanman JW. The mitochondrial genome: structure, transcription, translation and replication. Biochim Biophys Acta 1999;1410(2):103-123.
96. Shin MG, Kajigaya S, Levin BC, Young NS. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 2003;101(8):3118-3125.
97. Shin MG, et al. Mitochondrial DNA sequence heterogeneity in circulating normal human CD34 cells and granulocytes. Blood 2004;103(12):4466-4477.
98. Claessens Y-E, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99(5):1594-1601.
99. Tehranchi R, et al. Granulocyte colony-stimulating factor and erythropoietin treatment in MDS: A comparison of in vitro and in vivo effects on apoptosis and clonal growth. Leuk Res 2003;27(Suppl. 1):S71-72.
100. Drysdale J, et al. Mitochondrial ferritin: a new player in iron metabolism. Blood Cells Mol Dis 2002;29(3):376-383.
101. Cazzola M, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 2003;101(5):1996-2000.
102. Tehranchi R, et al. Aberrant mitochondrial iron distribution and maturation arrest characterizes early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106(1):247-253.
103. Nie G, Sheftel AD, Kim SF, Ponka P. Overexpression of mitochondrial ferritin causes cytosolic iron depletion and changes cellular iron homeostasis. Blood 2005;105(5): 2161-2167.
104. Cantor AB, Orkin SH. Hematopoietic development: a balancing act. Curr Opin Genet Dev 2001;11(5):513-519.
105. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 2002;21(21):3368-3376.
106. Hoefsloot LH, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997;89(5):1690-1700.
107. De Maria R, et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999; 401(6752):489-493.
108. Fontenay-Roupie M, et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 1999;106(2):464-473.
109. Kelley LL, et al. Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the Gl and S phases of the cell cycle without growth arrest or stabilization of wild-type p53. Mol Cell Biol 1994;14(6):4183-4192.
110. Kelley LL, et al. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: a mechanism for controlled rates of erythrocyte production. Blood 1993;82(8):2340-2352.
111. Sui X, Krantz SB, Zhao ZJ. Stem cell factor and erythropoietin inhibit apoptosis of human erythroid progenitor cells through different signalling pathways. Br J Haematol 2000;110(1):63-70.
112. Millot GA, Svinarchuk F, Lacout C, Vainchenker W, Dumenil D. The granulocyte colony-stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat5. Br J Haematol 2001;112(2):449-458.
113. Negrin R, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990;76(1):36-43.
114. Shuster MW, Thompson JA, Larson RA, Dugan. Randomized phase II study of recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with neutropenia secondary to myelodysplastic syndrome (MDS). Blood 1995;86:338a.
115. Greenberg P, et al. Phase-III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood 1993;82 (Suppl. 1)(10):A196.
116. Schouten HC, et al. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 1991;5(5):432-436.
117. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89(1):67-71.
118. Rose EH, Abels RI, Nelson RA, McCullough DM, Lessin L. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995;89(4):831-837.
119. Stasi R, et al. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes. Clin Cancer Res 1997;3(5):733-739.
120. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br J Haematol 1998;103(4):1070-1074.
121. Hast R, Wallvik J, Folin A, Bernell P, Stenke L. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res 2001;25(1):13-18.
122. Hellstrom-Lindberg E, et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. Leuk Lymph 1993;11(3-4):221-228.
123. Negrin RS, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996;87(10):4076-4081.
124. Remacha AF, et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 1999; 84(12):1058-1064.
125. Mantovani L, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000;109(2):367-375.
126. Ugo V, Casadevall N. [The place of growth factors in the treatment of myelodysplastic syndromes]. Pathol Biol (Paris) 2002;50(4):268-274.
127. Casadevall N, et al. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 2004;104(2): 321-327.
128. Hellstrom-Lindberg E. Approach to anemia associated with myelodysplastic syndromes. Curr Hematol Rep 2003;2(2):122-129.
129. Jadersten M, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor and erythropoetin: response and impact on survival in a long-term follow-up of 129 patients. Blood 2003;102(11): 184-5a.
130. Backx B, Broeders L, Lowenberg B. Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome. Blood 1992;80(5):1213-1217.
131. Hassan Z, Fadeel B, Zhivotovsky B, Hellstrom-Lindberg E. Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39. Exp Hematol 1999;27(8):1322-1329.
132. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78(11):2791-2808.
133. Miyamoto T, et al. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell 2002;3(1):137-147.
134. Ljung T, Bäck R, Hellstrom Lindberg E. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with pro-erythroid growth factors. Haematologica 2004;89(12):1446-1453.
135. Nilsson L, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000;96(6): 2012-2021.
136. Rigolin GM, et al. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors' response by fluorescence in situ hybridization on May-Grunwald-Giemsa-stained bone marrow samples. Br J Haematol 2002;119(3):652-659.